June 4-8, 2021; Online at https://conferences.asco.org/am
Updated data from the LEAP 004 trial of lenvatinib plus pembrolizumab in patients with advanced melanoma and confirmed progression on anti–PD-1/PD-L1 therapy resulted in durable responses and no new safety signals.